Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Drug Repositioning for Effective Prostate Cancer Treatment
KTH, Centres, Science for Life Laboratory, SciLifeLab. Istanbul Medeniyet Univ, Dept Bioengn, Istanbul, Turkey.;Marmara Univ, Dept Bioengn, Istanbul, Turkey..
Univ Gothenburg, Dept Chem & Mol Biol, Gothenburg, Sweden..
Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Mol & Clin Med, Gothenburg, Sweden..
Chalmers Univ Technol, Dept Biol & Biol Engn, Gothenburg, Sweden..
Show others and affiliations
2018 (English)In: Frontiers in Physiology, ISSN 1664-042X, E-ISSN 1664-042X, Vol. 9, article id 500Article, review/survey (Refereed) Published
Abstract [en]

Drug repositioning has gained attention from both academia and pharmaceutical companies as an auxiliary process to conventional drug discovery. Chemotherapeutic agents have notorious adverse effects that drastically reduce the life quality of cancer patients so drug repositioning is a promising strategy to identify non-cancer drugs which have anti-cancer activity as well as tolerable adverse effects for human health. There are various strategies for discovery and validation of repurposed drugs. In this review, 25 repurposed drug candidates are presented as result of different strategies, 15 of which are already under clinical investigation for treatment of prostate cancer (PCa). To date, zoledronic acid is the only repurposed, clinically used, and approved non-cancer drug for PCa. Anti-cancer activities of existing drugs presented in this review cover diverse and also known mechanisms such as inhibition of mTOR and VEGFR2 signaling, inhibition of PI3K/Akt signaling, COX and selective COX-2 inhibition, NF-kappa B inhibition, Wnt/beta - Catenin pathway inhibition, DNMT1 inhibition, and GSK-3 beta inhibition. In addition to monotherapy option, combination therapy with current anti-cancer drugs may also increase drug efficacy and reduce adverse effects. Thus, drug repositioning may become a key approach for drug discovery in terms of time- and cost-efficiency comparing to conventional drug discovery and development process.

Place, publisher, year, edition, pages
Frontiers Media S.A., 2018. Vol. 9, article id 500
Keywords [en]
prostate cancer, drug repositioning, non-cancer therapeutics, repurposing, approved drugs
National Category
Physiology
Identifiers
URN: urn:nbn:se:kth:diva-229015DOI: 10.3389/fphys.2018.00500ISI: 000432407100001Scopus ID: 2-s2.0-85047004631OAI: oai:DiVA.org:kth-229015DiVA, id: diva2:1211501
Funder
Science for Life Laboratory - a national resource center for high-throughput molecular bioscienceKnut and Alice Wallenberg Foundation
Note

QC 20180531

Available from: 2018-05-31 Created: 2018-05-31 Last updated: 2018-05-31Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textScopus

Authority records BETA

Uhlén, MathiasMardinoglu, Adil

Search in DiVA

By author/editor
Turanli, BesteUhlén, MathiasMardinoglu, Adil
By organisation
Science for Life Laboratory, SciLifeLab
In the same journal
Frontiers in Physiology
Physiology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 35 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf